Navigation Links
Schering-Plough Reports Long-Term Vicriviroc Data From Phase II Open-Label Extension Study in Treatment-Experienced HIV-Infected Patients
Date:9/14/2009

SAN FRANCISCO, Sept. 14 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported long-term data with vicriviroc, its investigational CCR5 receptor antagonist, from an ongoing, open-label extension of the Phase II VICTOR-E1 study in treatment-experienced HIV-infected patients. The results showed that vicriviroc plus optimized background therapy achieved durable virologic suppression and increased CD4 cell counts, and was generally well tolerated over two years of therapy. These 96-week results were presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).(1)

The study involved 85 treatment-experienced HIV-infected patients who received 48 weeks of open-label vicriviroc (30 mg once daily) plus an optimized antiretroviral regimen containing a ritonavir-boosted protease inhibitor after completion of 48 weeks of treatment in the double-blind phase of the VICTOR-E1 study (total of 96 weeks). More than half of these patients began open-label treatment with undetectable virus, i.e. an HIV-1 RNA level of less than 50 copies/mL, and about two-thirds had less than 400 copies/mL. Seventy patients remained on therapy at the time of the 96-week analysis. The virologic effect seen during the double-blind phase of the study was sustained in these patients during open-label vicriviroc treatment, with the percentage of patients achieving undetectable virus increasing over the course of therapy. Importantly, further improvements in CD4 counts were observed with longer vicriviroc therapy, with a mean increase of 50 cells/mm3 from week 48 of the double-blind study to the end of the 96-week period.

The data also showed that vicriviroc was generally well tolerated in this highly treatment-experienced population.
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma
2. Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV
3. Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
4. Schering-Plough Announces Results of the Early ACS Trial
5. Schering-Ploughs Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
6. Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
7. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
8. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
9. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
10. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
11. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Calif. , Aug. 28, 2014  STAAR Surgical Company ... marketer of implantable lenses and delivery systems for the eye, ... Health Care Conference at the New York Palace Hotel on ... Barry Caldwell , President and CEO will offer ... results, and operational developments and be joined by Steve ...
(Date:8/27/2014)... 2014 TWi Pharmaceuticals, Inc. (4180.TT) today announced ... United States Food and Drug Administration (FDA) on ... acetate 125mg/ml oral suspension, the generic equivalent to ... and under Hatch Waxman rules, it will be ... has completed the pre-launch preparation of the generic ...
(Date:8/27/2014)... Va. , Aug. 27, 2014 About ... the legs due to buildup of fatty plaque in ... in the aging patient population and in incidences of ... offers its Lower Extremity Arterial RevascularizatioN (LEARN) ... Endovascular specialists and interested residents and fellows ...
Breaking Medicine Technology:STAAR Surgical To Present At The Baird 2014 Health Care Conference 2TWi Pharmaceuticals Receives US FDA Final Approval on Generic Megestrol Acetate 125mg/ml Oral Suspension 2LEARN to Treat Peripheral Arterial Disease Patients 2LEARN to Treat Peripheral Arterial Disease Patients 3
... 11, 2010 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc. (NYSE Amex: ... leading fully-integrated specialty pharmaceuticals company in China, today announced financial ... ThirdQ uarter Highlights ... the third quarter of fiscal year 2009 Excluding an ...
... BOSTON, November 11, 2010 ... ... --> ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var r ...
Cached Medicine Technology:China Pharma Holdings, Inc. Reports Third Quarter 2010 Financial Results 2China Pharma Holdings, Inc. Reports Third Quarter 2010 Financial Results 3China Pharma Holdings, Inc. Reports Third Quarter 2010 Financial Results 4China Pharma Holdings, Inc. Reports Third Quarter 2010 Financial Results 5China Pharma Holdings, Inc. Reports Third Quarter 2010 Financial Results 6China Pharma Holdings, Inc. Reports Third Quarter 2010 Financial Results 7China Pharma Holdings, Inc. Reports Third Quarter 2010 Financial Results 8China Pharma Holdings, Inc. Reports Third Quarter 2010 Financial Results 9EvaluatePharma USA, Inc. Welcomed Into Boston Biotech Community by Mayor Menino 2EvaluatePharma USA, Inc. Welcomed Into Boston Biotech Community by Mayor Menino 3EvaluatePharma USA, Inc. Welcomed Into Boston Biotech Community by Mayor Menino 4EvaluatePharma USA, Inc. Welcomed Into Boston Biotech Community by Mayor Menino 5EvaluatePharma USA, Inc. Welcomed Into Boston Biotech Community by Mayor Menino 6EvaluatePharma USA, Inc. Welcomed Into Boston Biotech Community by Mayor Menino 7EvaluatePharma USA, Inc. Welcomed Into Boston Biotech Community by Mayor Menino 8
(Date:8/28/2014)... researchers place glue directly on the nerve stumps, but ... and allows glue to easily invade the nerve ends. ... to insert the nerve ends into the conduit because ... Xiangdang Liang and co-workers from the General Hospital of ... technique and defined the best parameters for its use ...
(Date:8/28/2014)... 2014 One in every 200 Ontarians has been ... of people living with the disease increasing by 64 ... study by researchers at the Institute for Clinical Evaluative ... and the Ottawa Hospital Research Institute. That puts Ontario ... world. , The study, published this week in ...
(Date:8/28/2014)... BCC Research ( http://www.bccresearch.com ) reveals in ... GLOBAL MARKETS , the global market for surgical navigation ... by the need for replacement of existing installations and ... the market is expected to grow to $631.9 million ... from 2013 through 2018. , While revenue generation will ...
(Date:8/28/2014)... Port Washington, New York (PRWEB) August 28, 2014 ... law firm that has spent many years fighting to ... comments that the decision to provide coverage to WTC ... report released by the U.S. Government Accountability Office (GAO). ... Watch on August 25th, the report is entitled ...
(Date:8/28/2014)... Clarity PSO , an operating division ... federal Patient Safety Organization (PSO) for another three-year period ... and Quality (AHRQ). Clarity PSO will continue to provide ... the true intentions of the Patient Safety and Quality ... and eager to continue our journey as a PSO ...
Breaking Medicine News(10 mins):Health News:Ontario has one of the highest rates of IBD in the world 2Health News:Global Market for Surgical Navigation Systems Expected to Reach $631.9 Million in 2018; ENT Systems Segment Leading With 10.4% CAGR 2Health News:Global Market for Surgical Navigation Systems Expected to Reach $631.9 Million in 2018; ENT Systems Segment Leading With 10.4% CAGR 3Health News:GAO Report Reaffirms Decision to Add Cancers to List of Illnesses Covered under the Zadroga Act, Parker Waichman LLP Comments 2Health News:GAO Report Reaffirms Decision to Add Cancers to List of Illnesses Covered under the Zadroga Act, Parker Waichman LLP Comments 3Health News:Clarity PSO Re-lists as a Patient Safety Organization and Continues to Advance Patient Safety 2Health News:Clarity PSO Re-lists as a Patient Safety Organization and Continues to Advance Patient Safety 3
... Therapeutics Inc. (Nasdaq: CRTX ), a specialty pharmaceutical company focused on ... today reported financial results for the three and six months ended June 30, ... , , Second quarter net revenues increase ... , , , ...
... , MARL, Germany, Aug. 11 Smith & ... SNN ) announced that the German District Court in Dusseldorf decided ... Kinetic Concepts, Inc (NYSE: KCI ) for a Preliminary ... Pressure Wound Therapy (NPWT) pump in Germany based on alleged infringement ...
... ... teeth whitening treatments , ... MN (PRWEB) August 11, 2009 -- Dr. Wilhelm , DMD MSD, announced today he ... Spraywhite , the only spray-on, in-home professional teeth whitening treatment. Made with Aerowhite™, WOW ...
... ... Healthcare, a Wake Forest, NC company specializing in retinal health assessment for diabetics. ... (PRWEB) August 11, ... Digital Healthcare, a Wake Forest, NC company specializing in retinal health assessment for diabetics. ...
... DALLAS Aug. 11, 2009 People diagnosed with type ... weight, developing low blood sugar and seeing their quality of ... Medical Center suggests that those fears are largely unfounded and ... defense, as opposed to a treatment of last resort for ...
... , , ... Obama,s efforts to position government-funded health care as a "cost-cutter" for ... to reduce health care costs, according to a national survey question ... The majority of respondents believe national tort reform laws ...
Cached Medicine News:Health News:Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 2Health News:Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 3Health News:Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 4Health News:Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 5Health News:Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 6Health News:Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 7Health News:Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 8Health News:Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 9Health News:Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 10Health News:Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 11Health News:Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 12Health News:Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 13Health News:Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 14Health News:German District Court Rules in Smith & Nephew's Favor in Patent Infringement Case 2Health News:German District Court Rules in Smith & Nephew's Favor in Patent Infringement Case 3Health News:Dr. Wilhelm, First Minnesota Cosmetic Dentist to Offer WOW Spraywhite Teeth Whitening 2Health News:Dr. Wilhelm, First Minnesota Cosmetic Dentist to Offer WOW Spraywhite Teeth Whitening 3Health News:The Jones Center for Diabetes & Endocrine Wellness Selects Retasure to Enhance Diabetes Care 2Health News:UT Southwestern physicians bust myths about insulin 2Health News:New Poll Shows Two-Thirds of Americans Don't Think Government Health Care Will Cut Costs 2
Designed for simple operation, the Model 515B pulse oximeter is ideal for use in any clinical setting; from emergency hospital transport to continuous monitoring in Anesthesia, Intensive Care and Gen...
... The Models 512 and 513 handheld ... This advanced technology is able to ... resolutions and speeds of 100 times ... in improved pulse oximeter performance during ...
... Whether it's for an emergency situation, bedside ... Handheld Capnograph / Pulse Oximeter delivers accurate ... This portable, handheld monitor now contains Nellcors ... compatible with OxiMax sensors. The NPB-75 monitor ...
The new Nellcor N-45 Handheld Pulse Oximeter is compatible with our complete line of OxiMax Pulse Oximetry Sensors, so clinicians have the convenience of Nellcors most advanced sensor technology in a...
Medicine Products: